Study record · Maridebart cafraglutide
Once-monthly maridebart cafraglutide for obesity
Weight loss ranged from -12.3% to -16.2% in obesity without diabetes and -8.4% to -12.3% in obesity with T2D, versus -2.5% and -1.7% placebo respectively.
Key result
Weight loss ranged from -12.3% to -16.2% in obesity without diabetes and -8.4% to -12.3% in obesity with T2D, versus -2.5% and -1.7% placebo respectively.
Study details
Study designRandomized, double-blind, placebo-controlled dose-ranging trial
PhasePhase II
PopulationAdults with obesity, with or without type 2 diabetes
Sample size592
RouteSubcutaneous
Regimen / exposure140, 280 or 420 mg every 4 weeks; one 420 mg every-8-week arm; escalation variants
Duration52 weeks
ComparatorPlacebo
Primary endpoint / questionPercent body-weight change; HbA1c in T2D cohort
Safety resultGI events were common and less frequent with lower starting doses / escalation; no unexpected safety signal emerged.
Key limitationsPhase II; antibody-peptide conjugate rather than a conventional peptide; long-term rare-event safety remains unresolved.
Registry / identifierPMID 40549887 / NCT05669599